Protein kinase A inhibition of macrophage maturation is accompanied by an increase in DNA methylation of the colonyâ  stimulating factor 1 receptor gene by Zasłona, Zbigniew et al.
Protein kinase A inhibition of macrophage maturation is
accompanied by an increase in DNA methylation of the colony-
stimulating factor 1 receptor gene
Zbigniew Zasłona, Anne M. Scruggs,
Marc Peters-Golden and Steven K.
Huang
Division of Pulmonary and Critical Care
Medicine, Department of Internal Medicine,
University of Michigan Medical School, Ann
Arbor, MI, USA
doi:10.1111/imm.12641
Received 22 March 2016; revised 17 June
2016; accepted 27 June 2016.
Correspondence: Steven K. Huang, Division
of Pulmonary and Critical Care Medicine,
Department of Internal Medicine, University
of Michigan Medical School, 6301 MSRB III,
1150 W Medical Center Dr, Ann Arbor, MI
48109, USA. Email: stehuang@umich.edu
Senior author: Steven K. Huang
Summary
Macrophage colony-stimulating factor 1 (CSF-1) plays a critical role in
the differentiation of mononuclear phagocytes from bone marrow precur-
sors, and maturing monocytes and macrophages exhibit increased expres-
sion of the CSF-1 receptor, CSF1R. The expression of CSF1R is tightly
regulated by transcription factors and epigenetic mechanisms. We previ-
ously showed that prostaglandin E2 and subsequent activation of protein
kinase A (PKA) inhibited CSF1R expression and macrophage maturation.
Here, we examine the DNA methylation changes that occur at the Csf1r
locus during macrophage maturation in the presence or absence of acti-
vated PKA. Murine bone marrow cells were matured to macrophages by
incubating cells with CSF-1-containing conditioned medium for up to
6 days in the presence or absence of the PKA agonist 6-bnz-cAMP. DNA
methylation of Csf1r promoter and enhancer regions was assayed by bisul-
phite pyrosequencing. DNA methylation of Csf1r decreased during normal
macrophage maturation in concert with an increase in Csf1r mRNA
expression. Treatment with the PKA agonist inhibited Csf1r mRNA and
protein expression, and increased DNA methylation at the Csf1r pro-
moter. This was associated with decreased binding of the transcription
factor PU.1 to the Csf1r promoter. Treatment with the PKA agonist inhib-
ited the responsiveness of macrophages to CSF-1. Levels of endogenous
PKA activity decreased during normal macrophage maturation, suggesting
that attenuation of this signalling pathway contributes to the increase in
CSF1R expression during macrophage maturation. Together, these results
demonstrate that macrophage maturation is accompanied by Csf1r
hypomethylation, and illustrates for the first time the ability of PKA to
increase Csf1r DNA methylation.
Keywords: colony-stimulating factor-1 receptor; DNA methyltransferase;
fms; macrophage colony-stimulating factor; protein kinase A.
Introduction
Circulating monocytes and tissue-recruited macrophages
are key defenders of host defence1 that differentiate from
myeloid precursors in a highly regulated process.2
Macrophage colony-stimulating factor 1 (CSF-1) is an
essential factor for monocyte/macrophage maturation.3
Mice with a natural mutation of Csf1 or with knockout
of the Csf1 gene exhibit substantial reductions in tissue-
derived mononuclear phagocytes.4 CSF-1 has furthermore
Abbreviation: ChIP, chromatin immunoprecipitation; CREB, cAMP response element binding; CSF1R, CSF-1 receptor; CSF, col-
ony-stimulating factor; DNMT, DNA methyltransferase; Epac, exchange protein activated by cAMP; FIRE, fms intronic regula-
tory element; IL, interleukin; LPS, lipopolysaccharide; PGE2, prostanglandin E2; PKA, protein kinase A; TET, ten–eleven
translocation; TNF, tumour necrosis factor; VASP, vasodilator-stimulated phosphoprotein
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been shown to increase macrophage proliferation, differ-
entiation and activation (reviewed in refs 5–7). Impair-
ment in CSF-1 expression is associated with a variety of
diseases including osteoporosis,8 atherosclerosis9 and Alz-
heimer’s disease,10 demonstrating the critical importance
of mature monocytes and macrophages in tissue home-
ostasis and disease prevention.
The actions of CSF-1 are mediated by its receptor,
CSF1R (also known as CSF-1R, M-CSF-R, fms, CD115),
whose expression is essential for mononuclear cell devel-
opment and maturation.11 CSF1R is expressed at low
levels in haematopoietic stem cells12,13 and is selectively
up-regulated during monocyte differentiation.14 Increased
expression and activation of CSF1R not only drives the
differentiation of myeloid progenitors into mature
mononuclear phagocytes, but can even reprogramme
granulocytes and pre-B and mature B lymphocytes into
expressing markers of monocyte/macrophage lineage.15–17
As a reflection of the critical importance of CSF1R,
expression of CSF1R is regulated at both the transcrip-
tional and post-transcriptional levels.18,19 Studies have
shown that the transcription factor PU.1 occupies the
Csf1r promoter even when Csf1r mRNA is expressed at
low levels in haematopoietic stem cells.14,20 Committed
monocytes and macrophages exhibit enhanced expression
of Csf1r mRNA due to transcription factor binding of the
fms intronic regulatory element (FIRE), and remodelling
of chromatin including histone acetylation and methyla-
tion.20 In addition, other epigenetic changes including
DNA methylation are also observed, especially in non-
myelopoietic cells such as fibroblasts and T cells, which
are hypermethylated at the Csf1r locus.16 Transcription of
Csf1r mRNA is therefore a consequence of a highly coor-
dinated interplay of transcription factors and epigenetic
modifications focused at the Csf1r promoter and enhan-
cer regions.
Prostaglandin E2 (PGE2) is a pleiotropic lipid mediator
that inhibits many macrophage functions including
phagocytosis and bacterial killing.21 Studies decades ago
showed that PGE2,
22,23 and other cAMP-elevating
agents,24 also inhibit CSF-1-induced macrophage differen-
tiation, proliferation and expression of urokinase plas-
minogen activator, but the operative mechanism for this
was unknown. We recently showed that PGE2, via sig-
nalling through the E prostanoid 2 receptor with subse-
quent increase in cAMP and protein kinase A (PKA)
activity, inhibited monocyte/macrophage maturation,
which was associated with a decrease in CSF1R expres-
sion.25 How CSF1R expression is inhibited by increased
PKA activity is unknown. As DNA methylation remains
one of the most fundamental epigenetic mechanisms and
has been shown to vary significantly within the Csf1r
locus between different cell types,16 we investigated how
DNA methylation of Csf1r changes during normal macro-
phage maturation, and how DNA methylation is affected
by PKA signalling. We found that DNA methylation of
Csf1r decreased during macrophage maturation, and that
exogenous activation of PKA resulted in an increase in
the DNA methylation at the Csf1r promoter, which was
associated with a decrease in PU.1 transcription factor
binding and Csf1r mRNA expression. Our studies there-
fore identify an ability for PKA, one of the most funda-
mental canonical signalling molecules, to affect the DNA
methylation of a key gene involved in monocyte/macro-
phage maturation.
Materials and methods
Cell culture and maturation of bone-marrow-derived
monocytes/macrophages
Murine macrophages were matured from bone marrow
precursors in vitro with the addition of recombinant
CSF-1, or conditioned medium from CSF-1-secreting
L929 cells, for up to 6 days.26,27 This well-established
approach results in relatively homogeneous primary
macrophages that are not conditioned by a specific tis-
sue microenvironment. Bone marrow cells were isolated
under aseptic conditions by flushing the marrow cavities
of femurs and tibiae of C57BL/6 mice purchased from
Jackson Laboratory (Bar Harbor, ME). All animal stud-
ies were approved by the University of Michigan Com-
mittee on the Use and Care of Animals. Bone marrow
cells were cultured for up to 6 days in RPMI-1640
(Thermo Fisher Scientific, Waltham, MA) containing
30% conditioned medium from L929 cells as previously
described.26,27 L929, a murine fibrosarcoma cell line that
synthesizes CSF-1, was cultured to confluence in Dul-
becco’s modified Eagle medium (Thermo Fisher Scien-
tific) with 10% fetal bovine serum (Hyclone, Logan,
UT) supplemented with 100 U/ml of penicillin/strepto-
mycin. To examine the effects of PKA activation, bone
marrow cells were treated with or without the selective
PKA agonist 6-bnz-cAMP (500 lM; Axxora, Farming-
dale, NY) at day 0 and again at day 3. In some experi-
ments, cells were treated at day 0 with 8-pCPT-20-O-
Me-cAMP (500 lM; Axxora), a selective agonist for the
alternative cAMP effector, exchange protein activated by
cAMP (Epac), or with IBMX (250 lM; BIOMOL, Farm-
ingdale, NY), an inhibitor of the cAMP-degradative
enzyme phosphodiesterase.
For small interfering RNA (siRNA) experiments, cells
were treated with 50 nM of control siRNA or combina-
tions of either DNA methyltransferase (DNMT)-3L
siRNA alone, DNMT3L siRNA with DNMT3a siRNA (at
50 nM each), or DNMT3L siRNA with DNMT3b siRNA
(at 50 nM each) (all from Qiagen, Valencia, CA) in Opti-
MEM (Thermo Fisher Scientific) at day 0 and again at
day 1. In other experiments, cells were treated at day 0
and again at day 1 with 50 nM of control siRNA or
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siRNA against the ten–eleven translocation (TET)
‘demethylases’ TET2 or TET3 (all from Dharmacon,
Lafayette, CO). Because cells were treated in OptiMEM,
20 ng/ml of CSF-1 (PeproTech, Rocky Hill, NJ)
was added to the medium to induce macrophage
differentiation.
Flow cytometry
Cells were suspended in PBS with 2 mM EDTA and
05% fetal calf serum. Fc receptor-mediated and non-
specific antibody binding were blocked by the addition
of excess CD16/CD32 (BD Biosciences, San Jose, CA).
Staining was performed at 4°C in the dark for 15 min.
The following monoclonal antibodies were used at
appropriate dilutions for staining: CD11b, (BD Bio-
sciences Pharmingen), CSF1R (BioLegend, San Diego,
CA), and F4/80 (eBioscience, San Diego, CA). A
FACSCalibur flow cytometer (BD Biosciences) was used
for flow cytometric characterization of cell populations,
and data were analysed using FLOWJO software (TreeStar,
Ashland, OR).
RT-PCR
RNA was isolated from cells using Trizol (Thermo Fisher
Scientific), made into cDNA, and amplified by quantita-
tive real-time PCR on the StepOnePlus Real-Time PCR
System (Applied Biosystems, Foster City, CA) using the
SYBR-green Master Mix (Applied Biosystems) and pri-
mers against murine Csf1r and b-actin. The primers were
as follows: for Csf1r: CGAGGGAGACTCCAGCTACA
(forward) and AGAAGTCGAGACAGGCCTCA (reverse);
for b-actin: CTGCCTGACGGCCAAGTC (forward) and
CAAGAAGGAAGGCTGGAAAAGAG (reverse). Primers
and probes for DNMT1 (Mm01151063_m1), DNMT3a
(Mm00432881_m1), DNMT3b (Mm01240113_m1),
DNMT3L (Mm00457635_m1), TET1 (Mm01169087_m1),
TET2 (Mm00524395_m1) and TET3 (Mm00805756_m1)
were obtained from Applied Biosystems. Relative gene
expression was determined by the comparative CT
method (DDCT) with b-actin used as a reference gene.
Bisulphite sequencing
DNA was isolated from cells using the Dneasy kit (Qia-
gen), and bisulphite converted using the EZ DNA Methy-
lation Kit (Zymo Research, Irvine, CA) as per the
manufacturers’ instructions. After bisulphite conversion,
regions of the murine Csf1r promoter, FIRE, and 1 kb
pair upstream of FIRE (FIRE –1 kb) were amplified with
the following primers: for Csf1r promoter: AAGGGGAA-
GAGGAGTTAGTG (forward) and CCCCTTTTCTCCCCT
TACCAT (reverse); for FIRE –1 kb: GATGAAGAATGGT-
TAGGATTAGGGTATTA (forward) and CCCTAAA
AATCACAAAACACATCTTTAAAT (reverse); for FIRE:
GATAATGGTTAGGAGGTTAGGGAAGTA (forward) and
AACTCAAACCCCCTATCAAATC (reverse). All reverse
primers were biotin-labelled – which allowed the ampli-
fied products to be isolated with sepharose beads,
denatured, and annealed to sequencing primers for
pyrosequencing on the Pyromark Q24 (Qiagen). The
sequencing primers for Csf1r promoter were: AGAGGAG
TTAGTGTAATAGATA, for FIRE –1 kb: AAGGGAAGGT
AGTGA, and for FIRE: GGGAAGTAGAAGTGAGA.
Chromatin immunoprecipitation
Bone marrow cells (1 9 107) were treated with or
without the PKA agonist 6-bnz-cAMP for 3 days in L929
conditioned medium. To perform chromatin immuno-
precipitation (ChIP), cells were incubated for 5 min in
1% formaldehyde to crosslink DNA with protein. Nuclear
material was isolated using non-ionic detergent buffers,
and chromatin was sheared to 200- to 500-bp fragments
by 20 min of sonication using a Covaris sonicator (Cov-
aris, Inc, Woburn, MA). Chromatin was incubated over-
night with antibody to PU.1 (1 : 25, #2266 Cell Signaling,
Danvers, MA) or isotype control. Chromatin was
immunoprecipitated using the ActiveMotif ChIP-IT
Express Kit (ActiveMotif, Carlsbad, CA) according to the
manufacturer’s protocol and reverse cross-linked. DNA
was cleaned using the DNA cleanup kit (Qiagen), and
isolated DNA was amplified by real-time PCR using pri-
mers targeting a CpG dense and a non-CpG dense region
of the Csf1r promoter. The primer sequences for the non-
CpG dense region (primer set 1) were CAGGAACAGA
CTTGAAGCGT (forward) and CCGCTGAACCAGGT
CTTCTTA (reverse) and for the CpG dense region
(primer set 2) were ATCCCCTGGAGGCTATGGAG (for-
ward) and TCTTTGCAACACTCCCCCAG (reverse).
Immunoblotting
Cell lysates were collected in lysis buffer (PBS contain-
ing 1% Nonidet P-40, 05% sodium deoxycholate, 01%
SDS) supplemented with protease inhibitor (Roche,
Basel, Switzerland) and phosphatase inhibitor (EMD
Chemicals, Gibbstown, NJ) cocktails. Proteins were
resolved by SDS–PAGE, transferred to nitrocellulose
membranes, and immunoblotted with antibodies against
the PKA-dependent phosphoproteins phosphorylated
vasodilator stimulated phosphoprotein (VASP, 1 : 1000,
Cell Signaling) or phosphorylated cAMP response ele-
ment binding (CREB, 1 : 1000 Cell Signaling), and the
loading control a-tubulin (1 : 1000, Sigma-Aldrich, St
Louis, MO). Membranes were incubated with the
appropriate horseradish peroxidase-conjugated secondary
antibodies and visualized using enhanced chemilumines-
cence reagent (GE Healthcare, Chalfont St Giles, UK).
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Densitometry was performed on visualized bands using
IMAGE J from the National Institutes of Health
(Bethesda, MD).
cAMP assay
Bone marrow cells were cultured in L929 supernatant for
6 days; cells were lysed in 01 M HCl and cAMP levels
were assayed using a colorimetric kit from Enzo (Farm-
ingdale, NY).
Interleukin-6, interleukin-10 and tumour necrosis factor-a
ELISA
Bone marrow cells were cultured in L929 supernatant
for 6 days in the presence or absence of 500 lM PKA
agonist (6-bnz-cAMP). Non-adherent cells were washed,
and adherent cells were re-plated at equal number for
1 hr stimulation with 20 ng/ml of recombinant CSF-1
(Peprotech, Rocky Hill, NJ) followed by 24 hr of stim-
ulation with 100 ng/ml of lipopolysaccharide (LPS)
(Sigma). Cell supernatants were cleared of cells by
centrifugation, and supernatant interleukin-6 (IL-6),
IL-10 and tumour necrosis factor-a (TNF-a) levels
were assayed by ELISA (R&D Systems, Minneapolis,
MN).
Statistical analysis
Data were analysed on GRAPHPAD PRISM 60 (GraphPad
Prism Software, San Diego, CA) using analyses of vari-
ance or Student’s t-test, as appropriate, with P < 005
defined as statistically significant. Data are expressed as
mean  SE measurement.
Results
Maturation of macrophages was associated with a
decrease in DNA methylation at the Csf1r promoter
and FIRE
Transcription of Csf1r has been previously shown to occur
at low levels in haematopoietic stem cells14 and to be selec-
tively up-regulated in mature macrophages, with its up-
regulation mediated by transcription factor assembly at the
promoter and FIRE enhancer region.20 Alterations in his-
tone modifications have been shown to contribute to the
increased expression of CSF1R during macrophage matura-
tion.20 There are six CpG loci closely clustered within a
100-bp region in the promoter/exon 2 region of Csf1r, and
a relatively high density of CpG loci clustered within 200-
bp regions located in the FIRE enhancer as well as 1 kb
upstream of FIRE (FIRE –1 kb) (Fig. 1a). Although methy-
lation-sensitive restriction enzymes were used to show on
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Figure 1. The DNA methylation of Csf1r is decreased during macrophage maturation. Cells from murine bone marrow were matured in L929
conditioned medium and DNA was collected from cells at days 0, 3 and 5. Bisulphite sequencing, as described in the Materials and methods, was
performed to assess the DNA methylation of CpG sites within the Csf1r gene, as illustrated (a). DNA methylation of CpG sites were analysed
within the gene promoter (b), 1 kb upstream of fms intronic regulatory element (FIRE –1 kb) (c), and FIRE (d) regions (n = 3). *P < 005.
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average that DNA methylation was low in the promoter
and FIRE regions of both myeloid progenitors and mature
macrophages,16 we used bisulphite sequencing to more sen-
sitively quantify the DNA methylation levels at each of the
CpG loci within the promoter, FIRE and FIRE –1 kb dur-
ing normal macrophage maturation. DNA methylation
levels decreased at each of the CpG sites within the pro-
moter (Fig. 1b) and FIRE –1 kb (Fig. 1c) regions as macro-
phages matured over time. Certain CpG sites in the FIRE
enhancer region also exhibited decreased methylation dur-
ing macrophage maturation, although baseline levels of
methylation were lower in the FIRE versus FIRE –1 kb and
promoter regions (Fig. 1d).
Activation of PKA inhibited Csf1r mRNA expression
and increased DNA methylation at the Csf1r
promoter
We previously demonstrated that PGE2 signalled through
PKA to inhibit macrophage maturation and that treat-
ment of bone marrow cells at day 0 with a PKA agonist,
6-bnz-cAMP, resulted in decreased numbers of CSF1R-
expressing F4/80+ CD11b+ mature macrophages.25 To
determine whether PKA operated at the transcriptional or
post-transcriptional level to inhibit expression of CSF1R,
bone marrow cells were treated at day 0 with the PKA
agonist 6-bnz-cAMP, and CSF1R protein and mRNA
levels were assayed at days 3 and 6 during macrophage
maturation. As expected, cell surface expression of CSF1R
increased between days 3 and 6 during macrophage mat-
uration, and expression was inhibited in the presence of a
PKA agonist (Fig. 2a). Examination of mRNA levels indi-
cated that the increase in CSF1R protein expression dur-
ing maturation and its inhibition with a PKA agonist
were accompanied by corresponding changes in Csf1r
mRNA (Fig. 2b).
Treatment with the PKA agonist was associated with
DNA hypermethylation of Csf1r promoter and
decreased PU.1 binding
We next examined the effect of activating PKA on the
DNA methylation of the Csf1r promoter, FIRE –1 kb
and FIRE regions. Treatment with the PKA agonist
resulted in increased Csf1r DNA methylation, particu-
larly within the promoter (Fig. 3a). A mild increase in
DNA methylation was also noted in the FIRE –1 kb
region (Fig. 3b), and no change in DNA methylation
was observed at the FIRE enhancer region (Fig. 3c). To
determine whether the increase in DNA methylation was
specific to the activation of PKA, bone marrow cells
were treated with 8-pCPT-2’-O-Me-cAMP, a cAMP ana-
logue that specifically activates the alternative cAMP
effector, the cAMP-activated guanine nucleotide
exchange protein Epac, but not PKA. Just as we had
previously shown that inhibition of macrophage matura-
tion by cAMP was a specific consequence of the activa-
tion of PKA and not Epac,25 treatment with the Epac
agonist did not increase the DNA methylation of Csf1r
promoter as was observed with the PKA agonist
(Fig. 3d).
PU.1 is a critical transcription factor involved in
monocyte/macrophage differentiation28,29 and it up-regu-
lates the expression of CSF1R.30,31 We next sought to
determine whether binding of PU.1 to the Csf1r pro-
moter was associated with the changes in DNA methyla-
tion observed after treatment with a PKA agonist.
Treatment of bone marrow cells with the PKA agonist
did not significantly affect expression of PU.1 (data not
shown). We next performed ChIP using an antibody
specific to PU.1 and observed that there was decreased
PU.1 binding to the Csf1r promoter in cells treated with
the PKA agonist (Fig. 4). The decrease in PU.1 binding
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Figure 2. Expression of Csf1r mRNA was decreased in bone marrow cells treated with a protein kinase A (PKA) agonist. Cells from murine bone
marrow were matured in L929 conditioned medium for 3 or 6 days in the presence or absence of the PKA agonist 6-bnz-cAMP (500 lM).
(a) Macrophage colony stimulating factor 1 receptor (CSF1R) cell surface protein expression was assayed by flow cytometry; the mean fluores-
cence intensity from a representative experiment of three independent experiments is shown. (b) Csf1r mRNA levels were assayed by RT-PCR
(n = 3). *P < 005.
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was observed; by comparison, an upstream region with-
out DNA hypermethylation showed no difference in
PU.1 binding between cells treated with or without
PKA. These results demonstrate that activation of PKA
leads to both DNA hypermethylation and decreased
PU.1 binding at specific regions within the Csf1r
promoter.
Macrophage maturation was associated with a
decrease in endogenous PKA activity
Protein kinase A can be activated by a myriad of signals
and, given the profound ability of an exogenous PKA
agonist to inhibit macrophage maturation, we sought to
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Figure 3. Treatment of bone marrow cells with
a protein kinase A (PKA) agonist was associ-
ated with an increase in Csf1r DNA methyla-
tion. (a–c) Cells from murine bone marrow
were matured in L929 conditioned medium for
3 or 5 days in the presence or absence of the
PKA agonist 6-bnz-cAMP (500 lM). The DNA
methylation of CpG sites within the Csf1r pro-
moter (a), FIRE –1 kb (b), and FIRE (c) were
assayed by pyrosequencing (n = 3). *P < 005.
(d) Bone marrow cells were treated with either
the PKA agonist 6-bnz-cAMP (500 lM), the
exchange protein activated by cAMP (Epac)
agonist 8-pCPT-20-O-Me-cAMP (500 lM), or
vehicle control and DNA methylation within
the Csf1r promoter was assayed. Shown is a
representative result from two independent
experiments.
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associated with a decrease in endogenous levels of PKA
activity. Phosphorylation of the PKA substrates VASP and
CREB are commonly used readouts of intracellular PKA
activity, and levels of phosphorylated VASP decreased
over time during normal macrophage maturation
(Fig. 5a). A similar decrease in phosphorylated CREB was
also observed (Fig. 5b) suggesting that diminished activity
of PKA accompanies normal macrophage maturation.
PKA is activated by cAMP, and intracellular levels of
cAMP were likewise lower at days 3 and 5 during macro-
phage maturation compared with day 0 (Fig. 5c). Treat-
ment of bone marrow cells with the phosphodiesterase
inhibitor IBMX, which inhibits cAMP degradation,
resulted in both higher levels of cAMP and decreased




Exon 1 Exon 2







IP: PU.1 IP: Isotype
control
IP: PU.1 IP: Isotype
control
Control





























Figure 4. Treatment of cells with the protein
kinase A (PKA) agonist resulted in decreased
PU.1 binding at the Csf1r promoter. Cells from
murine bone marrow were matured in L929
conditioned medium for 3 days in the presence
or absence of the PKA agonist 6-bnz-cAMP
(500 lM). Chromatin was isolated and
immunoprecipitated using an antibody to
PU.1 or isotype control. Real-time PCR was
performed using primers illustrated in (a), and
the relative enrichment from cells treated with
or without the PKA agonist is shown for pri-
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Figure 5. Macrophage maturation was associ-
ated with a decrease in endogenous cAMP
levels and protein kinase A (PKA) activity.
Cells from murine bone marrow were matured
to macrophages in L929 conditioned medium
over 5–6 days. Levels of phosphorylated
vasodilator-stimulated phosphoprotein (VASP)
(a) and phosphorylated cAMP responsive ele-
ment binding (CREB) protein (b) were assayed
by immunoblot. Representative blot (n = 3) is
shown. (c) Levels of cAMP were assayed from
the lysates of maturing cells at days 0, 3 and 5.
Results are normalized to control levels
(n = 3). Bone marrow cells were given IBMX
(250 lM), an inhibitor of the cAMP-degrada-
tive enzyme phosphodiesterase, for 6 days and
levels of cAMP (d) and CSF1R mRNA (e) were
assayed (n = 3). *P < 005.
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expression of CSF1R (Fig. 5d,e). This finding inversely
links cAMP levels to expression of CSF1R, indicating that
the increased expression of CSF1R during macrophage
maturation is attributable to the decrease in endogenous
levels of cAMP and PKA activity.
Treatment of bone marrow cells with a PKA agonist
inhibited macrophage maturation and cytokine
generation
To determine the functional consequence of inhibiting
macrophage maturation on generation of immunoregula-
tory cytokines – a property of mature macro-
phages – adherent bone marrow cells treated with or
without 6-bnz-cAMP (500 lM) for 6 days were re-plated,
washed and treated for 1 hr with CSF-1 (20 ng/ml) fol-
lowed by 24 hr of LPS (100 ng/ml), and IL-6, IL-10 and
TNF-a levels were assayed. Cells treated with the PKA
agonist for 6 days demonstrated markedly reduced abil-
ity to synthesize IL-6, IL-10 and TNF-a in response to
CSF-1 in the absence or presence of LPS (Fig. 6). As
previously reported, treatment with the PKA agonist did
not affect cell viability,25 suggesting that the impaired
responsiveness to CSF-1 and LPS is a consequence of
lower CSF1R expression and generally impaired bone
marrow macrophage maturation, and not due to
decreased cell numbers or apoptosis.
Expression of TET and DNMT proteins during
macrophage maturation
The DNMTs are responsible for the addition of methyl
groups to DNA and consist of three catalytically active
isoforms – DNMT1, DNMT3a and DNMT3b – and
DNMT3L, which is catalytically inactive, but facilitates
the actions of DNMT3a and DNMT3b. TET enzymes
were recently discovered to add hydroxyl groups to
methylated cytosine,32,33 resulting in base-excision repair
and active demethylation. Given that macrophage matu-
ration is associated with a decrease in Csf1r methylation,
and that methylation is increased when PKA is activated,
we examined the expression of various TET and DNMT
isoforms during macrophage maturation in the presence
or absence of a PKA agonist. Concurrent with a decrease
in Csf1r methylation, TET2 and TET3 expression
increased during macrophage maturation, which was
inhibited in the presence of a PKA agonist (Fig. 7a–c). In
parallel, expression of DNMT1, DNMT3b and DNMT3L
decreased during macrophage maturation, but only
DNMT3L expression increased in the presence of the
PKA agonist (Fig. 7d–g).
Silencing TET and DNMT expression did not
significantly alter Csf1r expression during macrophage
maturation or during treatment with a PKA agonist
As TET2 and TET3 expression increased during macro-
phage maturation and their actions are associated with
demethylation, we sought to determine whether silencing
TET2 or TET3 would result in persistent hypermethyla-
tion of Csf1r and decreased Csf1r mRNA levels during
maturation. Bone marrow cells were treated with control,
TET2 or TET3 siRNA at both day 0 and day 1, and levels
of Csf1r mRNA were determined at day 3. Neither silenc-
ing of TET2 nor TET3 inhibited the increase of Csf1r
expression at day 3 of maturation (Fig. 8a,b).
DNMT3L was the only DNMT isoform whose expres-
sion decreased with time as early as 3 days and also
increased in the presence of a PKA agonist, making it
the best candidate DNMT whose dynamic alterations in
expression might explain both the hypomethylation of






































































Figure 6. Inhibition of macrophage maturation with a protein kinase A (PKA) agonist attenuated the generation of immunoregulatory cytokines
in response to macrophage colony stimulating factor 1 (CSF-1) and lipopolysaccharide (LPS). Bone-marrow-derived monocytes/macrophages
(BMDM) were matured in L929 conditioned medium for 5 days in the presence or absence of the PKA agonist 6-bnz-cAMP (500 lM). Cells were
then re-plated and treated for 1 hr  MCSF (20 ng/ml) and then subsequently for 24 hr  LPS (100 ng/ml) and supernatants were assayed for
levels of interleukin-6 (IL-6) (a), IL-10 (b), and tumour necrosis factor-a (TNF-a) (c) (n = 3 for each experiment).
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hypermethylation of Csf1r seen during treatment with a
PKA agonist. We therefore used siRNA to silence
expression of DNMT3L to determine if this is sufficient
to abolish the actions of the PKA agonist. Although we
were able to achieve a robust knockdown of DNMT3L
expression with siRNA (Fig. 8c), the PKA agonist was
still able to decrease expression of CSF1R, suggesting
that the increase in DNMT3L by PKA is not responsible
for Csf1r hypermethylation (Fig. 8d). As DNMT3L itself
is enzymatically inactive and binds to DNMT3a and
DNMT3b to stimulate their activity,34 we also examined
levels of Csf1r mRNA when DNMT3a and DNMT3L,
and when DNMT3b and DNMT3L were silenced
together. Neither the combined silencing of DNMT3a
and DNMT3L nor the combined silencing of DNMT3b
and DNMT3L was sufficient to inhibit the ability of the
PKA agonist to suppress Csf1r expression (data not
shown).
Discussion
CSF1R is the major receptor for CSF-1, and up-regulation
of CSF1R is essential for monocyte/macrophage develop-
ment and differentiation.11 Prostaglandin E2 and other
cAMP-elevating agents were described many years ago to
inhibit CSF-1-mediated macrophage responses,22–24 and
we recently showed that through PKA signalling, these
mediators inhibit CSF1R expression and macrophage
maturation.25 Here, we show that activation of PKA led
to an increase in the DNA methylation of the Csf1r gene
at both the promoter and FIRE –1 kb regions. This was
associated with a decrease in PU.1 binding to the gene
promoter and a decrease in Csf1r mRNA levels. Macro-
phage maturation was accompanied by both a decrease in
basal levels of Csf1r DNA methylation and a decrease in
intrinsic PKA activity, suggesting that endogenous PKA
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Figure 7. Protein kinase A (PKA) altered expression of DNA methyltransferases (DNMTs) and Ten–Eleven Translocation (TET) proteins during
macrophage maturation. Bone marrow cells were treated with or without the PKA agonist 6-bnz-cAMP (500 lM) during macrophage maturation
and levels of (a) TET1, (b) TET2, (c) TET3, (d) DNMT1, (e) DNMT3a, (f) DNMT3b and (g) DNMT3L mRNA were assayed by RT-PCR; n = 6,
*P < 0.05 relative to Day 0; #P < 0.05 between treatments with and without the PKA agonist.
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suppressing the expression of Csf1r. These results demon-
strate how PKA signalling may influence the dynamic
changes in DNA methylation of key genes crucial to
monocyte/macrophage differentiation.
Protein kinase A was one of the first-described canoni-
cal signalling kinases, and has since been shown to modu-
late a range of diverse cellular functions including
proliferation, differentiation and survival,35,36 often
through the activation of other downstream mediators
and transcription factors such as CREB. Our results
demonstrated that PKA is also capable of inducing DNA
methylation, in this case, at the Csf1r gene locus. A previ-
ous study noted that PKA activation increased DNA
methylation and histone methylation in embryonic stem
cells.37 Ours is the first to show that PKA activation
affected DNA methylation in bone marrow cells.
The regulation of CSF1R expression is complex, and
levels of Csf1r mRNA levels are dependent on the
dynamic interaction of transcription factors, chromatin
remodelling, and DNA methylation changes at the Csf1r
promoter and enhancer regions.13,18 Transcription factors
such as PU.1 have been identified to sit poised on the
Csf1r promoter even in myeloid progenitors, which
express low levels of Csf1r mRNA,14 and through chro-
matin remodelling and transcription factor binding at
the FIRE enhancer region, transcription of Csf1r is up-
regulated in mature macrophages.20 These studies have
suggested that DNA methylation plays a minor role in
regulating Csf1r expression in haematopoietic stem cells
as methylation levels at the Csf1r promoter and FIRE
enhancer regions were low in early myeloid progenitors.16
Our study, however, suggests that the DNA methylation
levels of Csf1r in bone marrow cells are readily measur-
able and that DNA methylation levels in fact decrease
over time with macrophage maturation. Heterogeneity in
bone marrow cells and our use of a more sensitive, quan-
titative assay for DNA methylation at specific CpG loci
may explain differences between our data and other
studies.
Our results showed that decreased DNA methylation
levels are associated with increased Csf1r mRNA expres-
sion during maturation and that hypermethylation in the
presence of increased PKA activity is associated with its
decreased expression. We recognize that we cannot ascer-
tain whether DNA methylation changes are responsible
for Csf1r expression, or whether DNA methylation
changes are merely a consequence of changes in transcrip-
tion factors and chromatin modifications that regulate
Csf1r expression. Treatment of cells with the PKA agonist
inhibited PU.1 binding to the Csf1r promoter, and exami-
nation of other possible chromatin modifications induced
by the PKA agonist was beyond the scope of our study.
Expression of PU.1 was not significantly affected by treat-
ment with the PKA agonist, although it has been reported
that increased cAMP levels affect PU.1 transcription38









































































































































































Figure 8. Silencing of the Ten–Eleven Translo-
cation proteins TET2, TET3, or DNA methyl-
transferase 3L (DNMT3L) did not affect
expression of Csf1r in the presence or absence
of protein kinase A (PKA). Bone marrow cells
were treated with control small interfering
RNA (siRNA) or siRNA targeted against TET2
or TET3, as described in Materials and meth-
ods, and levels of TET2 and TET3 mRNA (a)
were assayed by RT-PCR (n = 3). *P < 005
relative to control siRNA. **P < 001 relative
to control siRNA. (b) Levels of Csf1r mRNA
were assayed by RT-PCR in cells treated with
TET2 or TET3 siRNA (n = 3). *P < 005 rela-
tive to control siRNA. NS, non-significant.
(c–d) Bone marrow cells were treated with
control siRNA or siRNA targeted against
DNMT3L in the presence or absence of the
PKA agonist 6-bnz-cAMP (500 lM), as
described in the Materials and methods. Levels
of DNMT3L mRNA (c, n = 3, *P < 005 rela-
tive to control siRNA) and Csf1r (d, n = 4,
*P < 005 relative to day 0) were assayed by
RT-PCR.
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contexts.39–41 Precedent for the ability of DNA methyla-
tion to regulate Csf1r expression, however, was best
exemplified in fibroblasts, T cells and leukaemic cells that
exhibited high levels of Csf1r methylation, which corre-
lated strongly with inhibition of Csf1r expression.16,42,43
We were unable to determine the relative importance of
increased Csf1r methylation versus inhibited demethylation
in response to activation of PKA, as expression of various
DNMT and TET enzymes all changed with time and with
PKA treatment. TET2 and TET3, which participate in DNA
hydroxymethylation and lead to demethylation,32,33 were
observed to increase with maturation, and decrease by the
PKA agonist. Silencing of TET2 and TET3 during normal
macrophage maturation, however, still resulted in an
increase in Csf1r expression, suggesting that progressive
hypomethylation of Csf1r cannot be explained purely by the
increase in TET2 or TET3 during normal maturation. Nota-
bly, we were only able to effectively silence TET2 and TET3
by ~50%, and complete knockdown of these genes may be
required to conclusively rule out a role for these enzymes in
mediating Csf1r hypomethylation. In addition, TET2 and
TET3 expression was not observed to increase until day 5,
indicating that these enzymes may still have a role in later
stages of macrophage maturation. Among the DNMT iso-
forms, only DNMT3L showed both a progressive loss of
expression during maturation and an increase in expression
with addition of the PKA agonist, suggesting its potential
involvement in Csf1r demethylation during maturation and
hypermethylation in the presence of active PKA. Targeted
silencing of DNMT3L, however, did not affect Csf1r mRNA
levels. Furthermore, combined silencing of both DNMT3L
and its interacting partners DNMT3a/DNMT3b did not
affect the ability of the PKA agonist to inhibit Csf1r expres-
sion. These data initially suggest that these enzymes are not
required for the hypermethylation of Csf1r observed after
the addition of a PKA agonist. However, an alternative
hypothesis is that hypomethylation of Csf1r during normal
maturation and hypermethylation in the presence of a PKA
agonist may be the consequence of a more complex interplay
between transcription factors and histone-modifying
enzymes that recruit DNMTs and TETs. PKA may interfere
with PU.1 binding, which may indirectly result in Csf1r
hypermethylation. Furthermore, the simultaneous silencing
of DNMT and over-expression of TET isoforms may be
what is necessary to inhibit the hypermethylation of Csf1r by
the PKA agonist. Further studies would also be needed to
determine whether PKA induces global hypermethylation or
hypomethylation of genes across the genome in macro-
phages and myeloid progenitors. Of note, we previously
reported that PGE2 increased expression of DNMT3a in
fibroblasts, resulting in global changes to DNA methylation
in these cells.44 Changes in DNMT and TET isoform expres-
sion in myeloid progenitors may therefore affect the DNA
methylation of other genes that may be important to macro-
phage maturation.
We treated cells with a PKA agonist to examine the
effects of PKA activity on Csf1r methylation, but we also
observed that macrophage maturation is itself associated
with a decrease in endogenous PKA activity. PKA is tradi-
tionally activated by cAMP, which can be increased by
various mediators including PGE2, which has been shown
to inhibit a variety of macrophage functions including
phagocytosis, bacterial killing and cytokine genera-
tion.21,45 PGE2 also inhibits macrophage differentiation
25
and haematopoiesis in general.46,47 Our results demon-
strating that PKA activation alters the DNA methylation
profile of a key gene in macrophage maturation may
partly explain how PGE2 inhibits haematopoiesis. How-
ever, we also previously showed that PGE2 levels do not
decline during macrophage maturation,25 so the decline
in endogenous cAMP levels and PKA activity during nor-
mal maturation is likely to reflect changes in some
cAMP-coupled receptor ligand other than PGE2. Epac is
another intracellular cAMP effector molecule, and a selec-
tive Epac agonist failed to alter Csf1r DNA methylation
levels. It is interesting to note that Epac expression has
been reported to increase during monocyte/macrophage
differentiation, and that Epac becomes functional in
mature macrophages.48 Taken together with our contrast-
ing results showing decreased endogenous PKA activity
during macrophage differentiation, these findings suggest
that there may be a coordinated switch in the effector
molecules engaged by cAMP – from PKA to Epac – dur-
ing macrophage differentiation. Finally, it should be men-
tioned that we did not examine whether PGE2 or PKA
post-transcriptionally regulates CSF1R expression, and a
recent study suggests that PGE2 may activate CSF1R
through phosphorylation.49
Mononuclear cell maturation in vitro was accomplished
herein through a well-established method described in the
literature.26,27 Freshly obtained bone marrow cells were
not pre-sorted in our studies and one might speculate
that the effects of PKA activation on Csf1r methylation
may be due to the expansion of haematopoietic stem cells
or other non-myeloid cell types rather than direct actions
on mononuclear phagocytes. However, as adherence is
characteristic of macrophages, wash steps and adherence
purification during maturation ensured that macrophages
were the predominant cell type in our studies. Although
our studies were performed in vitro, we have previously
shown that the ability of PKA to inhibit macrophage
development is applicable in vivo in thioglycollate-
induced peritonitis,25 with important consequences as
demonstrated in mouse models of infection and asthma.50
Furthermore, the decrease in endogenous PKA activity
observed during normal maturation indicates that media-
tors that regulate this signalling pathway are relevant for
physiological homeostasis.
CSF-1 activates many different macrophage functions,
including phagocytosis, production of reactive oxygen
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species, chemotaxis and microbial killing,51 and under-
standing regulation of CSF1R and its promoter DNA
methylation has functional implications beyond differenti-
ation. We observed that inhibition of CSF1R expression
by PKA was associated with diminished cytokine expres-
sion in the presence of LPS. Other studies have further-
more demonstrated that loss of CSF1R expression may
contribute to oncogenic transformation in leukae-
mia.42,52,53 In conclusion, we show that the progressive
increase in CSF1R expression during monocyte/macro-
phage maturation is accompanied by progressive
demethylation at the Csf1r gene and that PKA inhibition
of Csf1r mRNA expression correlated with DNA hyper-
methylation. PGE2, which activates PKA, can inhibit the
maturation of macrophages; we now show for the first
time that this intracellular signalling pathway is accompa-
nied by modulation of DNA methylation and DNA
methylation machinery. These studies demonstrate how
epigenetic levels change during haematopoiesis and their
regulation by PKA, and in a broader context, provide an
illustration of how intracellular signalling pathways are
capable of regulating DNA methylation patterns during
differentiation and development.
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